Literature DB >> 19693481

[Free/total PSA ratio in clinical and ambulatory application. Are different cutoffs justified?].

A Swoboda1, H-J Luboldt, H Rübben, C Börgermann.   

Abstract

Especially in the setting of total prostate-specific antigen (PSA) in the intermediate range of 4-10 ng/ml and a negative digital rectal examination, the use of the free/total (F/T) PSA ratio has proved to be an effective tool in prostate cancer screening. Whole blood should be analyzed as soon as possible after venipuncture to ensure optimal effectiveness of the F/T PSA ratio. If an immediate serum analysis is not possible, the serum should be frozen or stored at a maximum of 4 degrees C for a short period. Otherwise, when applying the F/T PSA cutoffs as recommended in the literature to a cohort with delayed analysis, a lack of specificity arises, and the initial advantage of reducing biopsies is minimized. To prevent loss of quality in a setting with delayed F/T PSA measurement, we recommend that physicians compare their own data critically with presented results and eventually adapt the cutoffs individually.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19693481     DOI: 10.1007/s00120-009-2075-4

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  19 in total

1.  Clinical usefulness of free PSA in early detection of prostate cancer.

Authors:  H J Luboldt; A Swoboda; C Börgermann; P Fornara; H Rübben
Journal:  Onkologie       Date:  2001-02

2.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

Authors:  W J Catalona; A W Partin; K M Slawin; M K Brawer; R C Flanigan; A Patel; J P Richie; J B deKernion; P C Walsh; P T Scardino; P H Lange; E N Subong; R E Parson; G H Gasior; K G Loveland; P C Southwick
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

3.  Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditions.

Authors:  K Jung; M Lein; B Brux; P Sinha; D Schnorr; S A Loening
Journal:  Clin Chem Lab Med       Date:  2000-12       Impact factor: 3.694

4.  Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff.

Authors:  H J Luboldt; A Bex; A Swoboda; J Hüsing; H Rübben
Journal:  Eur Urol       Date:  2001-02       Impact factor: 20.096

Review 5.  Review of diagnostic markers for prostate cancer.

Authors:  Fritz H Schröder
Journal:  Recent Results Cancer Res       Date:  2009

6.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.

Authors:  Gerrit Draisma; Ruth Etzioni; Alex Tsodikov; Angela Mariotto; Elisabeth Wever; Roman Gulati; Eric Feuer; Harry de Koning
Journal:  J Natl Cancer Inst       Date:  2009-03-10       Impact factor: 13.506

Review 7.  Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later.

Authors:  Kenneth J Pienta
Journal:  Urology       Date:  2009-05       Impact factor: 2.649

8.  Purification of a human prostate specific antigen.

Authors:  M C Wang; L A Valenzuela; G P Murphy; T M Chu
Journal:  Invest Urol       Date:  1979-09

9.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Authors:  William J Catalona; Jerome P Richie; Frederick R Ahmann; M'Liss A Hudson; Peter T Scardino; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

10.  Stability of serum prostate-specific antigen determination across laboratory, assay, and storage time.

Authors:  S J Jacobsen; G G Klee; H Lilja; G L Wright; J E Oesterling
Journal:  Urology       Date:  1995-03       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.